Körber has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a group of biopharmaceutical companies working to improve manufacturing technologies in the United States by conducting innovative research in areas such as big data, cell and gene therapy, and others.
The new membership is a significant step toward strengthening networks and achieving closer collaboration in biopharmaceutical manufacturing innovation. Körber is looking forward to not only contributing its expertise in areas like big data and cell and gene therapy, but also forging close bonds with other members of the NIIMBL community that will help the industry advance.
“We are happy to welcome Körber, a leading provider of services to the pharmaceutical industry including packaging, inspection and product handling technologies, to the NIIMBL member community. The software products and services portfolio of Körber’s Business Area Pharma, which includes the Werum PAS-X MES manufacturing execution system and the Werum PAS-X Savvy bioprocess data science software, will be a valuable addition to the innovation technologies available through our network,” tells Ruben Carbonell, Senior Technology Strategist at NIIMBL.
Rachit Jain, Global Cell and Gene Lead Software at Körber Business Area Pharma says: “Continuing our mission to save patient’s lives, we are excited to join NIIMBL in its quest to solve most challenging problems in the biomanufacturing space such as big data and cell & gene therapy initiatives. In this community, Körber will work with community members such as the big pharmas but also with NIST, FDA, and BARDA etc. as we race towards revolutionizing biopharmaceutical manufacturing.”